Actively Recruiting
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
Led by University of Florida · Updated on 2026-03-09
90
Participants Needed
1
Research Sites
215 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Two strategies have both proven to be effective in reducing bleeding complications while preserving efficacy compared with maintaining long-term DAPT with aspirin and a potent P2Y12 inhibitor: a) DAPT de-escalation (i.e., switching from prasugrel or ticagrelor to clopidogrel while maintaining aspirin) and b) potent P2Y12 inhibitor monotherapy (i.e., maintaining prasugrel or ticagrelor and dropping aspirin). These strategies have been tested in a number of trials and have led to changes in practice guidelines to consider either one of these strategies as bleeding reduction approaches among ACS patients undergoing PCI. However, comparative assessments between DAPT de-escalation and potent P2Y12 inhibitor monotherapy are lacking.
CONDITIONS
Official Title
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with chronic coronary syndrome who underwent PCI and have been on dual antiplatelet therapy with low-dose aspirin and prasugrel or ticagrelor for at least 30 days
- Patients with acute coronary syndrome who underwent PCI and have been on dual antiplatelet therapy with low-dose aspirin and prasugrel or ticagrelor for at least 3 months
- Age 18 years or older
- Able to provide written informed consent
You will not qualify if you...
- Prior history of stent thrombosis
- Currently treated with any oral anticoagulant or chronic low-molecular-weight heparin for venous thrombosis treatment
- Renal failure requiring dialysis
- Known bleeding disorders or coagulation problems
- Severe liver impairment
- Hemodynamic instability
- Allergy or hypersensitivity to clopidogrel
- Pregnant or breastfeeding women (women of childbearing age must use reliable birth control during the study)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Florida
Jacksonville, Florida, United States, 32209
Actively Recruiting
Research Team
D
Dominick J Angiolillo, MD,PhD
CONTACT
A
Andrea Burton, MPH, CCRP
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here